This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Enzon Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript

Enzon Pharmaceuticals, Inc. (ENZN)

Q1 2010 Earnings Call Transcript

May 10, 2010 5:00 pm ET

Executives

Craig Tooman – EVP of Finance, CFO

Alex Denner – Chairman

Ivan Horak – President, R&D and Chief Scientific Officer

Ralph Del Campo – COO

Richard Mulligan – Director

Analysts

Jim Tumbering – BMO Capital Markets

Caroline Corner – William Smith & Co.

Jeffrey Cohen – C.K. Cooper & Company

Ted Wachtell – Millennium Partners

Richard Mansouri – DellaCamera Capital

Brad Gold [ph] – Capital AU Consultants [ph]

Presentation

Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Enzon's first quarter earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. (Operator instructions) As a reminder, this conference is being recorded.

I would now like to turn the program over to our speaker, Craig Tooman, Executive Vice President and Chief Financial Officer of Enzon Pharmaceuticals. Sir, please go ahead.

Craig Tooman

Good morning and thank you for joining us today. Very pleased to be joined on the call today by my colleagues Ralph Del Campo, our Chief Operating Officer and Dr. Ivan Horak, our President of Research and Development. We’re also pleased to have two members of our executive committee participating in our call today, our Chairman, Dr. Alex Denner and Professor, Richard Mulligan.

Let me start by reminding you that during today’s conference call, we will be making forward-looking statements that represent the company's intentions, expectations, or beliefs concerning future events. These forward-looking statements are qualified by important factors set forth in today's press release and the company's filings with the SEC, which could cause actual results to differ materially from those in such forward-looking statements. Furthermore, information discussed on today's call is accurate as of today, and we do not intend to update it.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
ENZN $1.35 0.75%
AAPL $128.70 -0.19%
FB $78.81 -0.23%
GOOG $540.78 0.54%
TSLA $230.51 1.98%

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs